Vasopressin

Baxter International launched five new injectable pharmaceutical products in the U.S., totaling 10 product launches in 2024, reinforcing its leadership in high-value, specialty injectables and strengthening its Pharmaceutical business segment.

Endo, Inc. announced FDA approval for commercial production of Vasostrict at its new aseptic manufacturing facility in Indore, India, enhancing sterile injectable production capacity. The site, designed for specialized production, is expected to produce medicines in syringes and vials, with production slated to begin in 2026.

Endo's 20,000-square-foot Indore facility in India receives U.S. FDA approval for VASOSTRICT® production, enhancing sterile injectable capacity and future growth potential.

FDA approves Endo’s Vasostrict production for vasodilatory shock, to be manufactured at new 20,000ft² facility in Indore, India, starting 2026.

Angiotensin II, a synthetic vasopressor, effectively treats vasodilatory shock in the ATHOS-3 trial, achieving target mean arterial pressure. While no significant mortality differences were observed, post hoc analyses suggest survival benefits for high renin vasodilatory shock subgroups. Safety profiles showed no increase in serious adverse events, but a nonsignificant higher rate of deep vein thrombosis in the angiotensin II group. FDA approval includes warnings for thrombotic events, with reported differences in thromboembolic event rates between FDA and ATHOS-3 trial data. A systematic review by Caragata et al. found insufficient evidence to confirm or refute a consistent association between angiotensin II therapy and increased thromboembolic risk, highlighting the need for standardized diagnostic criteria and further research on early angiotensin II initiation.

Hennepin Healthcare seeks permission to enroll car crash victims in a clinical trial of two drugs reducing blood loss, aiming to determine if earlier treatment during transport improves survival rates. The study, part of the LITES Network, requires a federal exception for informed consent due to patients' unconsciousness or severe injury.